MARKET

CRVS

CRVS

Corvus Pharmaceu
NASDAQ
2.180
+0.040
+1.87%
Closed 16:00 07/19 EDT
OPEN
2.140
PREV CLOSE
2.140
HIGH
2.190
LOW
2.100
VOLUME
78.41K
TURNOVER
0
52 WEEK HIGH
2.860
52 WEEK LOW
1.050
MARKET CAP
136.36M
P/E (TTM)
-4.2636
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CRVS last week (0708-0712)?
Weekly Report · 6d ago
Weekly Report: what happened at CRVS last week (0701-0705)?
Weekly Report · 07/08 10:55
Weekly Report: what happened at CRVS last week (0624-0628)?
Weekly Report · 07/01 10:55
Weekly Report: what happened at CRVS last week (0617-0621)?
Weekly Report · 06/24 11:01
Corvus Pharmaceuticals Is Ready To Take Flight
Corvus Pharmaceuticals has shown positive growth and maturity over the past six months. The company is expanding its label and IP developments with trials in oncology and immunology. Corvus recently completed a capital raise, signaling confidence in their Phase 3 trials. The business is maturing with new leadership and increased clinical trial activity.
Seeking Alpha · 06/20 10:53
Weekly Report: what happened at CRVS last week (0610-0614)?
Weekly Report · 06/17 10:54
Weekly Report: what happened at CRVS last week (0603-0607)?
Weekly Report · 06/10 10:56
Weekly Report: what happened at CRVS last week (0527-0531)?
Weekly Report · 06/03 10:58
More
About CRVS
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.

Webull offers Corvus Pharmaceuticals Inc stock information, including NASDAQ: CRVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRVS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRVS stock methods without spending real money on the virtual paper trading platform.